Biotia Announces AMA Proprietary Laboratory Analyses (PLA) Code Granted for BIOTIA-ID Urine NGS Assay

New York, NY – July 15, 2025 — “The issuance of a test-specific billing code allows for greater transparency in claims submission and adjudication, thereby strengthening Biotia’s commercial strategy,” said Dr. Niamh O’Hara, Chief Executive Officer and Co-founder at Biotia. “This development supports the company’s commitment to making advanced genomic diagnostic testing broadly accessible across the United States.” The BIOTIA-ID Urine NGS Assay, a next-generation sequencing-based, in-vitro diagnostic test powered by Biotia’s proprietary BIOTIA-DX software, is now available in all 50 U.S. states, including with approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP).

“This PLA code issuance by the AMA CPT Editorial Panel marks a significant milestone for Biotia and the clinicians we serve,” said Dr. Dorottya Nagy-Szakal, Chief Medical Officer at Biotia. “It enables broader insurance reimbursement opportunities and expands patient access to our genomics-based urine test, which provides a precise, comprehensive alternative for patients with recurrent and complicated urinary tract infections (UTIs) and symptomatic patients who are culture-negative.”

The BIOTIA-ID Urine NGS Assay is the first genomics-based urine assay leveraging artificial intelligence (AI) approved in all 50 states, including New York. The assay is designed to diagnose recurrent and complicated UTIs, where traditional diagnostics often fail, to guide selection of antimicrobials.